{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:17:27Z","timestamp":1783678647899,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102588","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:13:24Z","timestamp":1780445604000},"page":"102588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Efficacy and Safety of Olaparib in Combination With Abiraterone for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Repair Gene Mutations"],"prefix":"10.1016","volume":"24","author":[{"given":"YiShui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9729-1288","authenticated-orcid":false,"given":"PengCheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102588_bib0001","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fonc.2019.00884","article-title":"Past, current, and future of immunotherapies for prostate cancer","volume":"9","author":"Boettcher","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102588_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.711258","article-title":"Development and verification of a prostate cancer prognostic signature based on an immunogenomic landscape analysis","volume":"11","author":"Cheng","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102588_bib0003","doi-asserted-by":"crossref","first-page":"307","DOI":"10.6004\/jnccn.2025.7032","article-title":"Epidemiology of metastatic castration-resistant prostate cancer in veterans nationwide","volume":"23","author":"Candelieri-Surette","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clgc.2026.102588_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/107327481502200114","article-title":"Current and emerging therapies for bone metastatic castration-resistant prostate cancer","volume":"22","author":"Frieling","year":"2015","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.clgc.2026.102588_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.36401\/JQSH-22-20","article-title":"Estimation of prostate cancer cost in Egypt from a societal perspective","volume":"6","author":"Elsisi","year":"2023","journal-title":"Glob J Qual Saf Healthc"},{"key":"10.1016\/j.clgc.2026.102588_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.12.014","article-title":"PARP inhibitor Olaparib and its combination therapy in metastatic castration-resistant prostate cancer: A systematic review and network meta-analysis","volume":"84","author":"Li","year":"2026","journal-title":"Eur. Urol. Open Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102588_bib0007","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/JS9.0000000000003338","article-title":"Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data","volume":"112","author":"Zhang","year":"2026","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.clgc.2026.102588_bib0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euf.2016.11.013","article-title":"Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor","volume":"2","author":"Tilki","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2026.102588_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9060067","article-title":"Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance","volume":"9","author":"Crona","year":"2017","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1016\/j.clgc.2026.102588_bib0010","first-page":"1","article-title":"Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer","volume":"10","author":"Boudadi","year":"2016","journal-title":"Clin Med Insight Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102588_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cjp2.203","article-title":"Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer","volume":"7","author":"Gonzalez","year":"2021","journal-title":"J pathol Clin Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102588_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102588_bib0013","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11523-025-01146-4","article-title":"Olaparib monotherapy or in combination with Abiraterone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA mutation","volume":"20","author":"Saad","year":"2025","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102588_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061416","article-title":"PARP inhibitors: a new horizon for patients with prostate cancer","volume":"10","author":"Congregado","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.clgc.2026.102588_bib0015","article-title":"PARP inhibitors in metastatic castration-resistant prostate cancer: unraveling the therapeutic landscape","volume":"14","author":"Al-Akhras","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.clgc.2026.102588_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241272929","article-title":"PARP inhibitors alone or in combination for prostate cancer","volume":"16","author":"Fenor de la Maza","year":"2024","journal-title":"Ther Adv Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102588_bib0017","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41391-024-00906-z","article-title":"Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey","volume":"28","author":"McManus","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.clgc.2026.102588_bib0018","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030411","article-title":"Histopathology of prostate cancer","volume":"7","author":"Humphrey","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"10.1016\/j.clgc.2026.102588_bib0019","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.7150\/thno.39838","article-title":"Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria","volume":"10","author":"Velez","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.clgc.2026.102588_bib0020","doi-asserted-by":"crossref","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, et al. RECIST 1.1\u2013Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. 2016; 62:138-45.","DOI":"10.1016\/j.ejca.2016.03.082"},{"issue":"12","key":"10.1016\/j.clgc.2026.102588_bib0021","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102588_bib0022","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102588_bib0023","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102588_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cells12101375","article-title":"Recent research advances in double-strand break and mismatch repair defects in prostate cancer and potential clinical applications","volume":"12","author":"Jaworski","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.clgc.2026.102588_bib0025","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/1878-0261.13577","article-title":"Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis","volume":"18","author":"Sugawara","year":"2024","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102588_bib0026","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11912-025-01669-z","article-title":"PARP inhibitors in the neoadjuvant setting; A comprehensive overview of the rationale for their use, past and ongoing clinical trials","volume":"27","author":"Habaka","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.clgc.2026.102588_bib0027","article-title":"Precision medicine in castration-resistant prostate cancer: advances, challenges, and the landscape of PARPi therapy-A narrative review","volume":"25","author":"Dimitrov","year":"2024","journal-title":"IntJMol Sci"},{"key":"10.1016\/j.clgc.2026.102588_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241258443","article-title":"Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?","volume":"16","author":"Garofoli","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102588_bib0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/bco2.156","article-title":"Serum testosterone and prostate cancer in men with germline BRCA1\/2 pathogenic variants","volume":"4","author":"Dias","year":"2023","journal-title":"BJUI Compass"},{"issue":"4","key":"10.1016\/j.clgc.2026.102588_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/path.6468","article-title":"Androgen receptor-mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer","volume":"267","author":"Sriraman","year":"2025","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102588_bib0031","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1987","article-title":"Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene","volume":"10","author":"Hockings","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clgc.2026.102588_bib0032","first-page":"519","article-title":"Mechanistic insights on localized to metastatic prostate cancer transition and therapeutic opportunities","volume":"15","author":"Yu","year":"2023","journal-title":"Res Rep Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102588_bib0033","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"Clarke","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:53:07Z","timestamp":1783677187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326000881"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102588","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Efficacy and Safety of Olaparib in Combination With Abiraterone for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Repair Gene Mutations","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102588"}}